johan smit
johan smit
Unknown affiliation
No verified email - Homepage
Title
Cited by
Cited by
Year
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
A Sparreboom, J Van Asperen, U Mayer, AH Schinkel, JW Smit, ...
Proceedings of the National Academy of Sciences 94 (5), 2031-2035, 1997
10521997
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
JW Jonker, JW Smit, RF Brinkhuis, M Maliepaard, JH Beijnen, ...
Journal of the National Cancer Institute 92 (20), 1651-1656, 2000
7832000
Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure
JW Smit, MT Huisman, O van Tellingen, HR Wiltshire, AH Schinkel
The Journal of clinical investigation 104 (10), 1441-1447, 1999
3921999
Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein
U Mayer, E Wagenaar, JH Beijnen, JW Smit, DKF Meijer, J van Asperen, ...
British journal of pharmacology 119 (5), 1038-1044, 1996
3441996
Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ...
Journal of clinical oncology 33 (30), 3401-3408, 2015
2982015
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs
MT Huisman, JW Smit, KML Crommentuyn, N Zelcer, HR Wiltshire, ...
Aids 16 (17), 2295-2301, 2002
2662002
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin …
A Younes, C Thieblemont, F Morschhauser, I Flinn, JW Friedberg, ...
The Lancet Oncology 15 (9), 1019-1026, 2014
2622014
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
AE van Herwaarden, E Wagenaar, CMM van der Kruijssen, ...
The Journal of clinical investigation 117 (11), 3583-3592, 2007
2222007
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir
MT Huisman, JW Smit, HR Wiltshire, RMW Hoetelmans, JH Beijnen, ...
Molecular pharmacology 59 (4), 806-813, 2001
2082001
Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
MT Huisman, JW Smit, AH Schinkel
Aids 14 (3), 237-242, 2000
2022000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein: potential clinical implications
JHM Schellens, M Maliepaard, RJ Scheper, GL Scheffer, JW Jonker, ...
Annals of the New York Academy of Sciences 922 (1), 188-194, 2000
1482000
Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted
JW Smit, AH Schinkel, B Weert, DKF Meijer
British journal of pharmacology 124 (2), 416-424, 1998
1251998
Mrp2 is essential for estradiol-17β (β-D-glucuronide)–induced cholestasis in rats
L Huang, JW Smit, DK Meijer, M Vore
Hepatology 32 (1), 66-72, 2000
1232000
Contribution of the murine mdr1a P‐glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption
JW Smit, AH Schinkel, M Müller, B Weert, DKF Meijer
Hepatology 27 (4), 1056-1063, 1998
1021998
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with …
B Venugopal, R Baird, RS Kristeleit, R Plummer, R Cowan, A Stewart, ...
Clinical Cancer Research 19 (15), 4262-4272, 2013
962013
Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters
DKF Meijer, JW Smit, M Müller
Advanced drug delivery reviews 25 (2-3), 159-200, 1997
811997
Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants
J de Jong, D Skee, J Murphy, J Sukbuntherng, P Hellemans, J Smit, ...
Pharmacology research & perspectives 3 (4), e00156, 2015
752015
Interactions between P‐glycoprotein substrates and other cationic drugs at the hepatic excretory level
JW Smit, E Duin, H Steen, R Oosting, J Roggeveld, DKF Meijer
British journal of pharmacology 123 (3), 361-370, 1998
741998
The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis.
IR Sondag-Tschroots, C Aaij, JW Smit, TE Feltkamp
Annals of the rheumatic diseases 38 (3), 248-251, 1979
631979
Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir
MT Huisman, JW Smit, HR Wiltshire, JH Beijnen, AH Schinkel
Journal of Pharmacology and Experimental Therapeutics 304 (2), 596-602, 2003
622003
The system can't perform the operation now. Try again later.
Articles 1–20